Stelazine

Trifluoperazine

Clinical data
AHFS/Drugs.com	Monograph
MedlinePlus	a682121
Pregnancy category	AU: C US: C (Risk not ruled out)
Routes of administration	oral, IM
ATC code	N05AB06 (WHO)
Legal status
Legal status	UK: POM (Prescription only) US: ℞-only
Pharmacokinetic data
Metabolism	Hepatic
Biological half-life	10–20 hours
Identifiers
IUPAC name 10-[3-(4-methylpiperazin-1-yl)propyl]- 2-(trifluoromethyl)-10H-phenothiazine
CAS Number	117-89-5 Y
PubChem CID	5566
IUPHAR/BPS	214
DrugBank	DB00831 Y
ChemSpider	5365 Y
UNII	214IZI85K3
ChEBI	CHEBI:45951 Y
ChEMBL	CHEMBL422 Y
PDB ligand	TFP (PDBe, RCSB PDB)
ECHA InfoCard	100.003.837
Chemical and physical data
Formula	C21H24F3N3S
Molar mass	407.497 g/mol
3D model (Jmol)	Interactive image
SMILES FC(F)(F)c2cc1N(c3c(Sc1cc2)cccc3)CCCN4CCN(C)CC4
InChI InChI=1S/C21H24F3N3S/c1-25-11-13-26(14-12-25)9-4-10-27-17-5-2-3-6-19(17)28-20-8-7-16(15-18(20)27)21(22,23)24/h2-3,5-8,15H,4,9-14H2,1H3 Y Key:ZEWQUBUPAILYHI-UHFFFAOYSA-N Y

Trifluoperazine (Eskazinyl, Eskazine, Jatroneural, Modalina, Stelazine, Terfluzine, Trifluoperaz, Triftazin) is a typical antipsychotic of the phenothiazine chemical class.

The primary application of trifluoperazine is for schizophrenia. Other official indications may vary country by country, but generally it is also indicated for use in agitation and patients with behavioural problems, severe nausea and vomiting as well as severe anxiety. Trials have shown a moderate benefit of this drug in patients with borderline personality disorder. Its use in many parts of the world has declined because of highly frequent and severe early and late tardive dyskinesia, a type of extrapyramidal symptom. The annual development rate of tardive dyskinesia may be as high as 4%.

A 2005 study of patients with generalized anxiety disorder noted that:

The results of a randomized placebo-controlled, flexible-dose acute treatment study indicate that the antipsychotic drug trifluoperazine had superior efficacy from the first week of double-blind treatment, although there were markedly more treatment emergent adverse events with trifluoperazine (62%,compared to 46% with placebo)

A 2006 study suggested that trifluoperazine may be able to reverse addiction to opioids.

A multi-year UK study by the Alzheimer's Research Trust suggested that this and other antipsychotic drugs commonly given to patients with Alzheimer's disease with mild behavioural problems often make their condition worse. The study concluded that

For most patients with AD, withdrawal of neuroleptics had no overall detrimental effect on functional and cognitive status and by some measures improved functional and cognitive status. Neuroleptics may have some value in the maintenance treatment of more severe neuropsychiatric symptoms, but this possibility must be weighed against the unwanted effects of therapy. The current study helps to inform a clinical management strategy for current practice, but the considerable risks of maintenance therapy highlight the urgency of further work to find, develop, and implement safer and more effective treatment approaches for neuropsychiatric symptoms in people with AD.